TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Brief Summary: The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Arm Label: Peginterferon Beta-1a Q2W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a) | Arm Label: Peginterferon Beta-1a Q4W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Intervention Type: DRUG; Name: BIIB017 (peginterferon beta-1a); Assigned to Arm(s): Peginterferon Beta-1a Q2W, Peginterferon Beta-1a Q4W, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Peginterferon Beta-1a Q4W, Placebo
B: Arm Label: Rebif®; Type: EXPERIMENTAL; Interventions: Drug: Rebif® | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone® | Intervention Type: DRUG; Name: Rebif®; Assigned to Arm(s): Rebif® | Intervention Type: DRUG; Name: Copaxone®; Assigned to Arm(s): Copaxone®
C: Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Arm Label: Alemtuzumab 12 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 12 mg | Arm Label: Alemtuzumab 24 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 24 mg | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 12 mg; Assigned to Arm(s): Alemtuzumab 12 mg | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 24 mg; Assigned to Arm(s): Alemtuzumab 24 mg
D: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: IFN-β-1a / 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a, Drug: Teriflunomide | Intervention Type: DRUG; Name: Interferon β-1a; Assigned to Arm(s): IFN-β-1a / 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): IFN-β-1a / 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Brief Summary: The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis.


Options:
A: Arm Label: Rebif®; Type: EXPERIMENTAL; Interventions: Drug: Rebif® | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone® | Intervention Type: DRUG; Name: Rebif®; Assigned to Arm(s): Rebif® | Intervention Type: DRUG; Name: Copaxone®; Assigned to Arm(s): Copaxone®
B: Arm Label: RNF 44 mcg three times weekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: RNF | Arm Label: RNF 44 mcg once weekly and placebo twice weekly for blinding; Type: ACTIVE_COMPARATOR; Interventions: Drug: RNF, Drug: Placebo | Arm Label: Placebo three times weekly; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RNF; Assigned to Arm(s): RNF 44 mcg once weekly and placebo twice weekly for blinding, RNF 44 mcg three times weekly | Intervention Type: DRUG; Name: RNF; Assigned to Arm(s): RNF 44 mcg once weekly and placebo twice weekly for blinding, RNF 44 mcg three times weekly | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo three times weekly, RNF 44 mcg once weekly and placebo twice weekly for blinding
C: Arm Label: Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Teriflunomide, Drug: Placebo | Arm Label: Teriflunomide 7 mg/7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg/14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg, Teriflunomide 14 mg/14 mg, Teriflunomide 7 mg/7 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg
D: Arm Label: Previously treated with alemtuzumab; Type: EXPERIMENTAL; Interventions: Biological: alemtuzumab | Arm Label: Previously treated with interferon beta-1a (Rebif®); Type: EXPERIMENTAL; Interventions: Biological: alemtuzumab | Intervention Type: BIOLOGICAL; Name: alemtuzumab; Assigned to Arm(s): Previously treated with alemtuzumab, Previously treated with interferon beta-1a (Rebif®)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Brief Summary: The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis.


Options:
A: Arm Label: Rebif®; Type: EXPERIMENTAL; Interventions: Drug: Rebif® | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone® | Intervention Type: DRUG; Name: Rebif®; Assigned to Arm(s): Rebif® | Intervention Type: DRUG; Name: Copaxone®; Assigned to Arm(s): Copaxone®
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol | Intervention Type: DRUG; Name: Glatiramer acetate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Albuterol placebo; Assigned to Arm(s): 1
C: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Copaxone; Assigned to Arm(s): Arm 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Study of the Effects of Selenium on Adenomatous Polyp Recurrence
Brief Summary: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Selenium may be effective in preventing the recurrence of adenomatous colorectal polyps.

PURPOSE: This randomized phase III trial is studying selenium to see how well it works in preventing the recurrence of polyps in patients with adenomatous colorectal polyps.


Options:
A: Intervention Type: DRUG; Name: Celecoxib (Celebrex); Assigned to Arm(s): N/A
B: Arm Label: Selenium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Selenium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Selenium | Intervention Type: DRUG; Name: Selenium; Assigned to Arm(s): Placebo, Selenium
C: Arm Label: Aggrenox, Clopidogrel placebo, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis | Arm Label: Aggrenox placebo, clopidogrel,, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Micardis, Drug: Aggrenox placebo, Drug: Clopidogrel | Arm Label: Aggrenox, clop placebo, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis placebo | Arm Label: Aggrenox plcebo, clop, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox placebo, Drug: Clopidogrel, Drug: Micardis placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo
D: Intervention Type: DRUG; Name: Naproxen Sodium (Aleve); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Celecoxib (Celebrex); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Study of Cetuximab (Erbitux™, C225) and Best Supportive Care Versus Best Supportive Care in Patients With Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma
Brief Summary: RATIONALE: Monoclonal antibodies, such as cetuximab, can target tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Best supportive care is the use of drugs and other treatments to improve the quality of life of patients. Combining cetuximab with best supportive care may slow the growth of the tumor and help patients live longer and more comfortably. It is not yet known whether cetuximab combined with best supportive care is more effective than best supportive care alone in treating metastatic epidermal growth factor receptor-positive colorectal cancer.

PURPOSE: This randomized phase III trial is studying cetuximab and best supportive care to see how well they work compared to best supportive care alone in treating patients with metastatic epidermal growth factor receptor-positive colorectal cancer.


Options:
A: Arm Label: Panitumumab plus best supportive care; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab | Arm Label: Best Supportive Care; Type: OTHER; Interventions: Other: Best supportive care | Intervention Type: OTHER; Name: Best supportive care; Assigned to Arm(s): Best Supportive Care | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab plus best supportive care
B: Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
C: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab, Drug: Leucovorin, Drug: Irinotecan, Drug: 5-Fluorouracil | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Leucovorin, Drug: Irinotecan, Drug: 5-Fluorouracil | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Arm A, Arm B
D: Arm Label: Cetuximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cetuximab | Arm Label: Panitumumab; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): Cetuximab | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Study of Cetuximab (Erbitux™, C225) and Best Supportive Care Versus Best Supportive Care in Patients With Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma
Brief Summary: RATIONALE: Monoclonal antibodies, such as cetuximab, can target tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Best supportive care is the use of drugs and other treatments to improve the quality of life of patients. Combining cetuximab with best supportive care may slow the growth of the tumor and help patients live longer and more comfortably. It is not yet known whether cetuximab combined with best supportive care is more effective than best supportive care alone in treating metastatic epidermal growth factor receptor-positive colorectal cancer.

PURPOSE: This randomized phase III trial is studying cetuximab and best supportive care to see how well they work compared to best supportive care alone in treating patients with metastatic epidermal growth factor receptor-positive colorectal cancer.


Options:
A: Arm Label: GSK2118436; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Arm Label: Dacarbazine (DTIC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine (DTIC) | Arm Label: Crossover; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Intervention Type: DRUG; Name: GSK2118436; Assigned to Arm(s): Crossover, GSK2118436 | Intervention Type: DRUG; Name: Dacarbazine (DTIC); Assigned to Arm(s): Dacarbazine (DTIC)
B: Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2
D: Arm Label: erlotinib; Type: EXPERIMENTAL; Interventions: Drug: erlotinib | Arm Label: gemcitabine/carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine/carboplatin | Intervention Type: DRUG; Name: erlotinib; Assigned to Arm(s): erlotinib | Intervention Type: DRUG; Name: gemcitabine/carboplatin; Assigned to Arm(s): gemcitabine/carboplatin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as vinorelbine, gemcitabine, docetaxel, paclitaxel, and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating non-small cell lung cancer.

PURPOSE: This randomized phase III trial is studying how well giving vinorelbine together with gemcitabine and docetaxel works compared to giving paclitaxel together with carboplatin in treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer.


Options:
A: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vinorelbine tartrate; Assigned to Arm(s): N/A
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Monotherapy (gemcitabine or vinorelbine) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Paclitaxel + Carboplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Monotherapy (gemcitabine or vinorelbine); Assigned to Arm(s): A
C: Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
D: Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Carboplatin | Arm Label: Arm A:; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Arm A:, Arm B | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Benefits & Risks of Popular Weight Loss Diets
Brief Summary: This study will compare the safety and effectiveness of three popular weight loss plans. These plans will be compared with the USDA Dietary Guidelines.


Options:
A: Intervention Type: BEHAVIORAL; Name: High and low glycemic index; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Atkins diet (extremely low carbohydrate); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Zone diet (low carbohydrate, high protein); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Ornish diet (very low fat); Assigned to Arm(s): N/A
C: Arm Label: New Nordic Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary intervention | Arm Label: Average Danish Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary intervention | Intervention Type: BEHAVIORAL; Name: Dietary intervention; Assigned to Arm(s): Average Danish Diet, New Nordic Diet
D: Arm Label: Low GI; Type: ACTIVE_COMPARATOR; Interventions: Other: Low GI | Arm Label: High GI; Type: EXPERIMENTAL; Interventions: Other: High GI | Intervention Type: OTHER; Name: Low GI; Assigned to Arm(s): Low GI | Intervention Type: OTHER; Name: High GI; Assigned to Arm(s): High GI

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Benefits & Risks of Popular Weight Loss Diets
Brief Summary: This study will compare the safety and effectiveness of three popular weight loss plans. These plans will be compared with the USDA Dietary Guidelines.


Options:
A: Arm Label: Vegan Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Intervention Meetings, Behavioral: Physical Activity, Behavioral: Podcasts/Mailings | Arm Label: Omnivorous (Omni) Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Intervention Meetings, Behavioral: Physical Activity, Behavioral: Podcasts/Mailings | Intervention Type: BEHAVIORAL; Name: Dietary Intervention Meetings; Assigned to Arm(s): Omnivorous (Omni) Diet, Vegan Diet | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Omnivorous (Omni) Diet, Vegan Diet | Intervention Type: BEHAVIORAL; Name: Podcasts/Mailings; Assigned to Arm(s): Omnivorous (Omni) Diet, Vegan Diet
B: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Low Carbohydrate Diet; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Atkins diet (extremely low carbohydrate); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Zone diet (low carbohydrate, high protein); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Ornish diet (very low fat); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 1 Year, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Persistent, Inadequately Controlled Allergic Asthma
Brief Summary: A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks. In patients with allergies, there is an exaggerated production of IgE in response to specific substances such as pollens. Omalizumab is a new drug that inactivates IgE. This study tested the safety and efficacy of omalizumab against asthma attacks in children with allergic asthma.


Options:
A: Arm Label: Non-drug interventional group; Type: OTHER; Interventions: Drug: Short Acting Beta Agonist (SABA) | Intervention Type: DRUG; Name: Short Acting Beta Agonist (SABA); Assigned to Arm(s): Non-drug interventional group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MEDI-563 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MEDI-563 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Comp. | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: MEDI-563; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: MEDI-563; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Placebo Comp.; Assigned to Arm(s): 4 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 5
C: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Drug: Fluticasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Fluticasone | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): Omalizumab, Placebo
D: Arm Label: OAT + Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Other: Optimized asthma therapy | Arm Label: Optimized Asthma Treatment (OAT); Type: ACTIVE_COMPARATOR; Interventions: Other: Optimized asthma therapy | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): OAT + Omalizumab | Intervention Type: OTHER; Name: Optimized asthma therapy; Assigned to Arm(s): OAT + Omalizumab, Optimized Asthma Treatment (OAT)

Answer: C